European Commission approves first twice-yearly HIV medication
Long-term Canadian study shows HIV-exposed children have worse health outcomes
Vitamin D and calcium supplements suggested to avert bone disease in people taking tenofovir-based ART and PrEP
Long-acting cabotegravir and rilpivirine may be feasible for people without viral suppression
A cure must be a cure for all: why more HIV cure research in Africa is needed
Social support can buffer the effects of stigma on suicidality among young people living with HIV
Package of person-centred care improves viral suppression for young people living with HIV in Kenya and Uganda
The challenges integrating U=U into HIV care around the world
Rate of neural tube defects is no higher on dolutegravir
